Pharmacogenetics of quetiapine in healthy volunteers: Association with pharmacokinetics, pharmacodynamics, and adverse effects

International Clinical Psychopharmacology

Volumn 30, Issue 2, 2015, Pages 82-88

  Cabaleiro, Teresa ^a   López Rodríguez, Rosario ^a,b   Román, Manuel ^a   Ochoa, Dolores ^a   Novalbos, Jesús ^a   Borobia, Alberto ^c   Carcas, Antonio ^c   Abad Santos, Francisco ^a,b  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

adverse effects; pharmacodynamics; pharmacogenetics; pharmacokinetics; quetiapine

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; QUETIAPINE; AGT PROTEIN, HUMAN; ANGIOTENSINOGEN; CYP1A1 PROTEIN, HUMAN; CYP1A2 PROTEIN, HUMAN; CYP2C19 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; CYTOCHROME P450; CYTOCHROME P450 1A2; DIBENZOTHIAZEPINE DERIVATIVE; DOPAMINE 3 RECEPTOR; DRD3 PROTEIN, HUMAN; NEUROLEPTIC AGENT; PROLACTIN;

ABDOMINAL PAIN; ADULT; ARTICLE; ASTHENIA; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG SAFETY; FAINTNESS; FEMALE; GENETIC MARKER; GENETIC POLYMORPHISM; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NIGHTMARE; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; SOMNOLENCE; VOMITING; XEROSTOMIA; YOUNG ADULT; ADOLESCENT; BLOOD; CLINICAL TRIAL; GENETIC ASSOCIATION; GENETICS; GENOTYPE; MIDDLE AGED; SEXUAL DEVELOPMENT;

ADOLESCENT; ADULT; ANGIOTENSINOGEN; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 CYP2C9; CYTOCHROME P-450 ENZYME SYSTEM; DIBENZOTHIAZEPINES; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROLACTIN; RECEPTORS, DOPAMINE D3; SEX CHARACTERISTICS; YOUNG ADULT;

EID: 84922411945     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000047     Document Type: Article

References (37)

1. Adler CM, Fleck DE, Brecher M, Strakowski SM (2007). Safety and tolerability of quetiapine in the treatment of acute mania in bipolar disorder. J Affect Disord 100 (Suppl 1):S15-S22.
2. Aichhorn W, Marksteiner J, Walch T, Zernig G, Saria A, Kemmler G (2006a). Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol 21:81-85.
3. Aichhorn W, Whitworth AB, Weiss EM, Marksteiner J (2006b). Secondgeneration antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Saf 29:587-598.
4. Almoguera B, Riveiro-Alvarez R, Gomez-Dominguez B, Lopez-Rodriguez R, Dorado P, Vaquero-Lorenzo C, et al. (2010). Evaluating a newly developed pharmacogenetic array: screening in a Spanish population. Pharmacogenomics 11:1619-1625.
5. Arranz MJ, de Leon J (2007). Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 12:707-747.
6. Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S (2013). Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 11:CD006625.
7. Bakken GV, Rudberg I, Molden E, Refsum H, Hermann M (2011). Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. Ther Drug Monit 33:222-226.
8. Bakken GV, Molden E, Knutsen K, Lunder N, Hermann M (2012). Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro. Drug Metab Dispos 40:1778-1784.
9. Basile VS, Masellis M, Potkin SG, Kennedy JL (2002). Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 11:2517-2530.
10. Cabaleiro T, López-Rodríguez R, Ochoa D, Román M, Novalbos J, Abad-Santos F (2013). Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. Hum Psychopharmacol 28:205-214.
11. Castberg I, Skogvoll E, Spigset O (2007). Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry 68:1540-1545.
12. Cohrs S, Röher C, Jordan W, Meier A, Huether G, Wuttke W, et al. (2006). The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology (Berl) 185:11-18.
13. Cuyàs E, Olano-Martín E, Khymenets O, Hernández L, Jofre-Monseny L, Grandoso L, et al. (2010). Errors and reproducibility of DNA array-based detection of allelic variants in ADME genes: PHARMAchip. Pharmacogenomics 11:257-266.
14. Davies MA, Setola V, Strachan RT, Sheffler DJ, Salay E, Hufeisen SJ, Roth BL (2006). Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. Pharmacogenomics J 6:42-51.
15. Davies MA, Conley Y, Roth BL (2011). Functional SNPs in genes encoding the 5-HT2A receptor modify the affinity and potency of several atypical antipsychotic drugs. Biol Res Nurs 13:55-60.
16. de Borja Goncąlves Guerra A, Castel S, Benedito-Silva AA, Calil HM (2005). Neuroendocrine effects of quetiapine in healthy volunteers. Int J Neuropsychopharmacol 8:49-57.
17. Food and Drug Administration. Quetiapine label (2009). Available at: http://www. accessdata.fda.gov/drugsat.fda-docs/label/2011/020639s049s054lbl.pdf. [Accessed 2 September 2013].
18. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS (2008). The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83:234-242.
19. Kane JM (1999). Pharmacologic treatment of schizophrenia. Biol Psychiatry 46:1396-1408.
20. Kinon BJ, Gilmore JA, Liu H, Halbreich UM (2003). Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 28:69-82.
21. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmöller J (2004). Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9:442-473.
22. Li KY, Li X, Cheng ZN, Peng WX, Zhang BK, Li HD (2004). Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia. Acta Pharmacol Sin 25:390-394.
23. López-Rodríguez R, Roman M, Novalbos J, Pelegrina ML, Ochoa D, Abad-Santos F (2011). DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers. J Clin Psychopharmacol 31:555-562.
24. Malhotra AK, Murphy GM Jr, Kennedy JL (2004). Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161:780-796.
25. Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari GI, Bareggi SR (2007). Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 46:359-388.
26. McClay JL, Adkins DE, Aberg K, Stroup S, Perkins DO, Vladimirov VI, et al. (2011). Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry 16:76-85.
27. Meltzer HY, Okayli G (1995). Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 152:183-190.
28. Mihaljevi-Peles A, Sagud M, Bozina N, Zivkovi M, Jovanovi N (2010). Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy. Psychiatr Danub 22:335-337.
29. Myers LS, Steele MK (1989). The brain renin-angiotensin system and prolactin secretion in female rats: influence of ovarian hormones. J Neuroendocrinol 1:299-303.
30. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T (1999). Genetic polymorphism in the 5?-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 125:803-808.
31. Prior TI, Baker GB (2003). Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 28:99-112.
32. Roke Y, van Harten PN, Boot AM, Buitelaar JK (2009). Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol 19:403-414.
33. Szekeres G, Kéri S, Juhász A, Rimanóczy A, Szendi I, Czimmer C, Janka Z (2004). Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 124B:1-5.
34. Tarazi FI, Zhang K, Baldessarini RJ (2001). Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 297:711-717.
35. Tejedor D, Castillo S, Mozas P, Jiménez E, López M, Tejedor MT, et al. Spanish FH Group (2005). Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin Chem 51:1137-1144.
36. Urichuk L, Prior TI, Dursun S, Baker G (2008). Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab 9:410-418.
37. Wittmann M, Hausner H, Köstlbacher A, Hajak G, Haen E (2010). Individual clearance and therapeutic drug monitoring of quetiapine in clinical practice. Neuro Endocrinol Lett 31:203-207.